45results about "Osteogenic factor" patented technology

To provide a bone morphogenetic protein-9 (BMP-9) variant in which heterotopic ossification side effect is alleviated, and a fusion thereof.SOLUTION: Provided are a bone morphogenetic protein-9 (BMP-9) variant expressed by a specific amino acid sequence, BMP-9 variant-Fc fusion protein in which an Fc fragment of immunoglobulin is connected to the BMP-9 variant, and a pharmaceutical composition for treating cardiopulmonary disease which contains the BMP-9 variant or the BMP-9 variant-Fc fusion protein as an active ingredient. The cardiopulmonary disease is one or more kinds selected from the group consisting of cardiac infarction, hypertension, pulmonary hypertension, myocardial fibrosis, and pulmonary fibrosis.SELECTED DRAWING: Figure 4b

The invention relates to an mRNA (messenger Ribonucleic Acid) medicine and application thereof in treating pulmonary arterial hypertension. In particular, the present invention relates to polynucleotides encoding peptides comprising a BMP9 active molecule and / or an ACTRIIA ligand trapping agent, lipid nanoparticles comprising said polynucleotides, and therapeutic uses thereof.

The application provides a bone morphogenetic protein BMP-2 recombinant protein, and the amino acid sequence of the BMP-2 recombinant protein is shown as SEQ ID No. 1. The coding gene, the expression plasmid, the prokaryotic expression vector and the prokaryotic expression method are also disclosed. The prokaryotic expression system is adopted, and a solubilization tag is creatively introduced, so that the inclusion body expression is converted into soluble expression. The BMP-2 is expressed in the form of inclusion body in the prokaryotic system, the protein is converted into soluble expression by adding the solubilization tag, the difficulty of protein separation and purification is reduced, the purification cycle is shortened, and the purification efficiency is improved.

In one aspect, the invention relates to synthetic molecules, compositions and pharmaceutical compositions, which are useful for delivering a bioactive moiety to a site of injury. Also disclosed are methods of treating a tendon injury, methods of treating a fracture, methods of treating a bone stress injury, methods of enhancing incorporation of allograft tissues, methods of promoting repair or regeneration of enthesis tissue during or after an orthopedic surgical procedure, and method of treating osteoporosis, osteoarthritis and / or cartilage defects using the disclosed molecules, compositions and pharmaceutical compositions.

To provide a composition that significantly improves bone healing and accelerates tissue regrowth.SOLUTION: The present invention provides a chimeric polypeptide that comprises (i) one or more β-tricalcium phosphate (β-TCP)-binding sequence(s), wherein at least one of the one or more β-TCP-binding sequence(s) is selected from the group consisting of specific sequences and (ii) a mammalian growth factor. The present invention also provides a composition containing the chimeric polypeptide.SELECTED DRAWING: Figure 1A

This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.

This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.

This application provides a composition containing PENK protein and its application in promoting osteoblast osteogenic differentiation. Compared with the prior art, this application has the following advantages: The pro-PENK recombinant protein and the PENK-containing composition provided in this application, after being applied to cells with osteogenic potential, enhance osteogenic performance through interaction with CBFB protein, and can significantly promote osteogenic differentiation. Compared with the existing bone morphogenetic protein 2 (BMP recombinant protein), the osteogenic effect is superior. Furthermore, experiments have verified that the osteogenic differentiation effect of pro-PENK recombinant protein on osteoblasts is dose-dependent. This application further verifies that the combined use of low doses of PENK recombinant protein and BMP recombinant protein has a more significant cellular osteogenic effect than the use of either at high doses alone.

The present disclosure provides peptides, or variants or analogs thereof, with between 8 and 30 amino acids, having growth factor receptor-binding capability, wherein the RMSD value of the structure coordinates of said peptide, variant or analog thereof with respect to PEPREF is 2.45Å (Angstroms) or less.

A polypeptide or a modifier thereof having an effect of promoting bone formation; can be used for preventing and / or treating bone diseases.

The instant disclosure relates to methods for converting mammalian definitive endoderm (DE) cells into specific tissue(s) or organ(s) through directed differentiation. In particular, the disclosure relates to formation of esophageal tissue and / or organoids formed from differentiated definitive endoderm.

To provide human colonic organoids in vitro, usable for determining the efficacy and / or toxicity of potential therapeutics for a disease selected from the group consisting of colitis, colon cancer, polyposis syndrome and / or irritable bowel syndrome.SOLUTION: The disclosure provides a human colonic organoid (HCO), where the human colonic organoid comprises epithelium and mesenchyme and expresses SATB2, MUC2 and / or MUC5B.SELECTED DRAWING: Figure 1A

A cell culture medium for culturing organoid containing at least two types of components selected from the group consisting of insulin-like growth factor 1 (IGF1), fibroblast growth factor 2 (FGF2) and epiregulin (EREG), and at least one type of component among the following components i) to iii): i) Wnt agonist, ii) bone morphogenetic protein (BMP) inhibitor, and iii) transforming growth factor-β (TGF-β) inhibitor.

The invention relates to the technical field of biological medicine, in particular to an extra CCAAT box in a low-heart-rate long-life mammal GDF11 promoter capable of reducing the resting heart rate and promoting longevity. According to the invention, a regulatory element capable of co-evolution with prolonged life and low heart rate is found by using bioinformatics and gene editing animals. On the basis, the invention provides a functional control region in a GDF11 gene promoter region, the functional region comprises two CCAAT boxes, and the positions of the two CCAAT boxes are respectively located at the 194th-198th basic groups of the GDF11 gene promoter. The functional control region in the GDF11 gene promoter region provided by the invention can promote the longevity, low heart rate and senescence delaying of mammals, can also be used for constructing animal models with reduced resting heart rate and / or senescence delaying, and provides a promising way for research and development of treatment means for senescence and heart rate related diseases.

Methods are provided for delaying onset or progression of kidney damage, or treating kidney disease, in a subject who has type 1 diabetes or type 2 diabetes or glomerular disease. The methods comprise administering to a subject with type 1 or type 2 diabetes or glomerular disease an effective amount of an agent capable of inhibiting NBL1 activity, and in particular, capable of inhibiting NBL1-mediated toxicity of human podocytes. In some embodiments, the agent is an antibody capable of binding to human NBL1.

The present invention relates to mRNA drugs and their use in the treatment of pulmonary arterial hypertension. In particular, the present invention relates to polynucleotides encoding a peptide comprising a BMP9 active molecule and / or an ACTRIIA ligand trap, lipid nanoparticles comprising said polynucleotides and their therapeutic use.

Provided are dual-affinity fusion proteins including an affibody domain specific for a therapeutic protein, and including a localization domain specific for a structural bone component. The therapeutic protein can include bone morphogenetic protein 2 (BMP-2), vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF-2), platelet-derived growth factor (PDGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4), or glial derived neurotrophic factor (GDNF). Also provided are compositions that include the dual-affinity fusion proteins, affibodies and the corresponding therapeutic proteins, and / or a medical material used to treat a wound, or a bone or cartilage injury or disease. Also provided are methods of using the compositions, for example to treat bone injuries, bone diseases, cartilage injuries, cartilage diseases, and wounds. In some examples, the composition includes at least two different dual-affinity fusion proteins specific for the same therapeutic protein, but have different disassociation constants (KD).

The present disclosure provides methods of differentiating pluripotent stem cells, including induced pluripotent stem cells, into lineage-specific floor plate midbrain progenitor cells, determined dopaminergic neuronal progenitor cells, committed dopaminergic neuronal progenitor cells and / or dopaminergic neuronal cells. Also provided are compositions uses thereof, such as for treating neurodegenerative diseases and conditions, including Parkinson's disease, and articles of manufacture and kits for use thereof.

The present invention relates to a biocompatible matrix material embedded with a quantity of yeast-generated extracellular vesicles (yEVs) configured for the in-situ delivery of one or more therapeutic polynucleotides contained within the yEV, preferably to a diseased or injured tissue or organ.

A method for repairing a bone defect of a patient includes providing a ceramic scaffold configured for filling the bone defect, loading the scaffold with growth factor transduced cells incorporating a gene that encodes a growth factor essential for bone formation, placing the ceramic scaffold with the growth factor transduced cells in or across the bone defect, and stabilizing the ceramic scaffold with the growth factor transduced cells in the patient until the bone defect is healed. An assembly for repairing a bone defect includes a ceramic scaffold configured for spanning the bone defect and a culture of live growth factor transduced cells incorporating a gene that encodes a growth factor essential for bone formation loaded onto the ceramic scaffold.

This document provides methods and materials involved in promoting bone growth. For example, this document provides vectors designed to express (a) a nucleotide sequence encoding a bone morphogenetic protein 2 (BMP2) polypeptide and / or (b) a nucleotide sequence encoding an interleukin-1 receptor antagonist (IL-1Ra) polypeptide for promoting bone growth. In some cases, one or more vectors provided herein can be administered to a mammal (e.g., a human) having a disease, disorder, or condition associated with bone loss to treat the mammal. For example, a population of a single vector provided herein can be used to increase expression of a BMP2 polypeptide and an IL-1Ra polypeptide by cells within a mammal (e.g., a human) having a disease, disorder, or condition associated with bone loss to promote bone growth within the mammal.

This present disclosure provides a stuffer sequence for optimal packaging and productivity of a recombinant adeno-associated virus (rAAV) vector. This present disclosure also provides methods of designing, manufacturing, and using such stuffer sequence.

In one embodiment, the present invention relates to synthetic molecules, compositions, and pharmaceutical compositions useful for delivering bioactive portions to the site of injury. Also disclosed are methods for treating tendon injuries, fractures, bone stress injuries, enhancing the integration of allograft tissue during or after orthopedic surgery, promoting the repair or regeneration of tendon attachment tissue, and methods for treating osteoporosis, osteoarthritis, and / or cartilage defects using the disclosed molecules, compositions, and pharmaceutical compositions.

Disclosed herein are compositions, culture systems, and methods for stable clonal expansion of renal unit progenitor cells (NPCs) and generation of renal unit organoids. The compositions and culture systems allow for high purity and clone scalable NPC populations, which enable genomic range screening and rapid, efficient and scalable organ-like models of kidney disease.

The present invention relates to a novel peptide derived from the copine 7 protein and having both cell permeability and bone tissue regeneration ability, and to a use of the peptide. The peptide according to the present invention has excellent bone tissue regeneration ability and is therefore useful for treating a disease requiring bone regeneration, such as osteoporosis. Particularly, by also having cell permeability, the peptide does not require the attachment of a separate peptide or addition of another preparation for the cell permeation thereof and thus can be conveniently applied in orthopedics and the like requiring various surgical regeneration treatments.

The described invention provides soft tissue grafts, hard tissue grafts, and composite soft / hard tissue grafts and methods of producing such grafts. The grafts comprise a three-dimensional carrier matrix, a growth factor composition comprising an autologous platelet-rich fibrin and a cell culture composition comprising a culture medium, a population of cells suspended in the culture medium, and cells impregnated on or in a surface of osteoconductive particles.

The present disclosure discloses a nucleic acid molecule including SEQ ID No. 1. The nucleic acid molecule encodes for a recombinant bone morphogenetic protein-2 (rBMP-2) inside a mammalian cell.

Methods and materials for making and using extracellular vesicles (EVs) engineered to include BMP2 or BMP2 in combination with BMP7, and cells that can be used to generate such EVs, are provided herein. For example, methods and materials for generating EVs that include BMP2 or BMP2 and BMP7, and methods and materials for using such EVs to induce bone formation, are provided. Methods and materials for making and using minicircle DNAs (mcDNAs) to overexpress BMP2 or BMP2 and BMP7 also are provided herein. For example, methods and materials for generating mcDNAs that encode BMP2 or BMP2 and BMP7, and methods and materials for using such mcDNAs to induce bone formation, are provided.